Blood Banks Must Boost Convalescent Plasma Supply

Blood Banks Must Boost Convalescent Plasma Supply

Federal health officials are working with the American Red Cross and other blood donation organizations in an effort to boost supplies of convalescent plasma, a promising COVID-19 treatment, The Wall Street Journal reported.

Convalescent plasma is a blood product collected from people who have recovered from COVID-19 that carries antibodies that could help those sick with the disease recover.

While convalescent plasma hasn’t been FDA approved as a safe and effective treatment for COVID-19, about 28,000 patients have received it and a report published last month in the journal Mayo Clinic Proceedings said that serious adverse events occurred in less than 1 percent of patients receiving the plasma.

The Biomedical Advanced Research and Development Authority has asked the Red Cross and the blood donation industry’s group, America’s Blood Centers, if they can collect about 400,000 units of convalescent plasma, according to the Journal. America’s Blood Centers represents 46 nonprofit blood centers in the U.S.


Click Here to Read More >

Subscribe Our Newsletter
to get Coronavirus Updates